Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30

Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 12, 2026Score 3/30

$47.78+0.63 (+1.34%)

Close on Nov 13, 2026Market cap $6.75BP/E –Yield –

Arrowhead Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Arrowhead Pharmaceuticals's EV/EBITDA was 28.3× on Apr 30, 2026, against 105.7× a year earlier.

Period	Period end	Value	Change (pts)
2026	Apr 30, 2026	28.3×	−39.1
2025	Dec 31, 2025	67.4×	−681.3
2020	May 29, 2020	748.7×	+657.4
2019	Dec 31, 2019	91.3×	–

Parsed from the XBRL in Arrowhead Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Nov 17, 2011
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing